Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Interest & Investment Income: 2009-2023

Historic Interest & Investment Income for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2023 value amounting to $47,000.

  • Gyre Therapeutics' Interest & Investment Income fell 83.33% to $47,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $384,000, marking a year-over-year decrease of 30.56%. This contributed to the annual value of $717,000 for FY2022, which is 1738.46% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Interest & Investment Income of $47,000 as of Q3 2023, which was down 35.62% from $73,000 recorded in Q2 2023.
  • Over the past 5 years, Gyre Therapeutics' Interest & Investment Income peaked at $1.0 million during Q1 2020, and registered a low of -$66,000 during Q4 2020.
  • In the last 3 years, Gyre Therapeutics' Interest & Investment Income had a median value of $73,000 in 2023 and averaged $84,636.
  • In the last 5 years, Gyre Therapeutics' Interest & Investment Income plummeted by 112.39% in 2021 and then skyrocketed by 4,100.00% in 2022.
  • Gyre Therapeutics' Interest & Investment Income (Quarterly) stood at $489,000 in 2019, then slumped by 84.87% to -$66,000 in 2020, then surged by 106.06% to $4,000 in 2021, then surged by 4,100.00% to $168,000 in 2022, then plummeted by 83.33% to $47,000 in 2023.
  • Its Interest & Investment Income was $47,000 in Q3 2023, compared to $73,000 in Q2 2023 and $96,000 in Q1 2023.